Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 18/20 | 0.55 |
| ▸ | KDR | P35968 | 14/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.54 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.54 |
| ▸ | LCK | P06239 | 2/20 | 0.54 |
| ▸ | YES1 | P07947 | 2/20 | 0.54 |
| ▸ | CSK | P41240 | 2/20 | 0.54 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.54 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.54 |
| ▸ | STK10 | O94804 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | LYN | P07948 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | HCK | P08631 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | FGR | P09769 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13634006 | 0.84 | SRC (0.61) | SRCKDREGFRPKMYT1LCK | |
| SCHEMBL30227057 | 0.83 | SRC (0.60) | SRCKDREGFRPKMYT1LCK | |
| SCHEMBL16742220 | 0.83 | SRC (0.65) | SRCKDREGFRPKMYT1LCK | |
| SCHEMBL6387383 | 0.82 | SRC (0.45) | SRCKDREGFRPKMYT1LCK | |
| SCHEMBL16747751 | 0.81 | SRC (0.58) | SRCKDREGFRPKMYT1LCK | |
| SCHEMBL16742218 | 0.79 | SRC (0.58) | SRCKDREGFRPKMYT1LCK | |
| SCHEMBL3275626 | 0.79 | SRC (0.68) | SRCKDREGFRPKMYT1LCK | |
| SCHEMBL28343783 | 0.78 | EGFR (0.57) | SRCKDREGFRPKMYT1LCK | |
| SCHEMBL4266694 | 0.78 | SRC (0.53) | SRCKDREGFRPKMYT1LCK | |
| SCHEMBL30901625 | 0.78 | SRC (0.55) | SRCKDREGFRPKMYT1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676480-A1 | INHIBITORS OF DNA POLYMERASE THETA | Breakpoint Therapeutics GmbH (DE) | 2026-01-14 | — | — | EP | disclosed |
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119053604-A | Heterocyclic compounds for the treatment of ERK5 mediated diseases | 癌症研究技术有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-118891065-A | Anticancer therapy using radioactive PARP inhibitors | 癌症研究技术有限公司 | 2024-11-01 | — | — | CN | disclosed |
| WO-2024189493-A1 | INHIBITORS OF DNA POLYMERASE THETA | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-09-19 | — | — | WO | disclosed |
| CN-118510761-A | Crystalline forms of ATR inhibitors | 上海德琪医药科技有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-118317949-A | Isoindolines as PMS2 inhibitors | 奈奥芬莱有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118317954-A | Indoline as PROTAC compound | 奈奥芬莱有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-117693507-A | Inhibitor compounds | 奈奥芬莱有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117480162-A | Compounds for the treatment or prophylaxis of PRMT5 mediated diseases | 阿古诺治疗有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117460508-A | Combination therapy comprising a METTL3 inhibitor and an additional anticancer agent | 斯托姆治疗有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-117295736-A | Benzo [ C ] [2,6] naphthyridine derivatives, compositions thereof and therapeutic uses thereof | 剑桥实业有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-110621675-B | Tricyclic compounds useful for the treatment of proliferative diseases | 阿古诺治疗有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-115996907-A | Inhibitors of MLH1 and/or PMS2 for cancer treatment | 奈奥芬莱有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-1871769-B1 | CRYSTALLINE FORMS OF THE COMPOUND 4-(6-CHLORO-2,3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE. | ASTRAZENECA AB (SE) | 2017-02-22 | — | — | EP | disclosed |
| US-8304417-B2 | Crystalline forms of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline | ASTRAZENECA AB (SE) | 2012-11-06 | — | — | US | disclosed |
| US-20090099196-A1 | Chemical Process | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| EP-1871769-A2 | PROCESS FOR THE PREPARATION OF 4-(6-CHLORO-2,3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE,THEIR INTERMEDIATES AND CRYSTALLINE SALTS THEREOF | AstraZeneca AB (SE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006064217-A2 | PROCESS FOR THE PREPARATION OF 4-(6-CHLORO-2, 3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-l-YL) ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE , THEIR INTERMEDIATES AND CRYSTALLINE SALTS THEREOF | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099196-A1 | Chemical Process | CYP3A5, CYP3A43, CYP3A7 | SRC 529/4885KDR 2658/4885EGFR 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.